[7]. Bauer TM, et al. Clinical Management of Adverse Events Associated with Lorlatinib. Oncologist. 2019; 24(8):1103-1110. [8].Solomon B et al. Lorlatinib vs crizotinib in the first-line treatment of patients with advanc...
CNS cancer articles withinCell Death & Disease Featured Article 27 January 2025|Open Access PLIN1 suppresses glioma progression through regulating lipid metabolism Kui Luo ,Kai Zhuang &Zhifei Wang Article 26 January 2025|Open Access Overexpression of miR-124 enhances the therapeutic benefit of TMZ tre...
[13] Cho BC, Ahn M-J, Kang JH, Soo RA, Reungwetwattana T, Yang JC-H, et al. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non Small-Cell Lung Cancer: Results From ...
2024 ASCO 2024年5月31日-6月4日,2024年美国临床肿瘤学会(ASCO)年会将于美国芝加哥正式召开,本届年会的主题为“癌症诊疗的科学与艺术:从关怀到治愈(The Art and Science of Cancer Care: From Comfort to Cure)”。作为规模最大、最具权威的临床肿瘤学会议之一,本次大会共设200余个专场,为国际肿瘤学者提供了...
6. Pasi A. Janne, David Planchard, Kunihiko Kobayashi, et al. CNS Efficacy of Osimertinib With or Without Chemotherapyin Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Onc...
[1]Shi Y et al., Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG), ELCC 2022, Oral Presentation, Abstract 1O [2...
癌症、中枢神经系统(CNS)疾病和罕见病都是威胁人类健康的重大疾病。在已知的200多种癌症中,许多仍“无药可医”;CNS疾病让上亿人饱受困扰,而现有治疗普遍难以改变疾病的发展轨迹;罕见病影响近4亿患者,但超过…
CNS-Directed Cancer Treatment and Child Adjustment: Moderating Effects of Maternal ParentingAdrien M Winning, MAKatianne Howard Sharp, PhDAmanda C Ferrante, BAJessica Ralph, BALeandra Desjardins, PhDDebra L Friedman, MDTammi K Young-Saleme, PhD...
Cancer research needs neuroscience and neuroscientists The nervous system can drive the initiation, growth, spread, and therapy resistance of cancer, and cancer can manipulate the nervous system in ways that further support disease progression. Tumors growing within the brain or elsewhere in the body ...
5.Scagliotti, G.V., et al.,Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of t...